Literature DB >> 14734476

In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor.

Rana P Singh1, Girish Sharma, G U Mallikarjuna, Sivanandhan Dhanalakshmi, Chapla Agarwal, Rajesh Agarwal.   

Abstract

PURPOSE: Diet composition is an important etiologic factor in prostate cancer (PCA) growth and has significant impact on clinical PCA appearance. Because inositol hexaphosphate (IP6) is a dietary phytochemical present in cereals, soy, legumes, and fiber-rich foods, we evaluated efficacy of IP6 against PCA growth and associated molecular events. EXPERIMENTAL
DESIGN: DU145 cells were injected into nude mice, and animals were fed normal drinking water or 1 or 2% IP6 in drinking water for 12 weeks. Body weight, diet, water consumption, and tumor sizes were monitored. Tumors were immunohistochemically analyzed for proliferating cell nuclear antigen, terminal deoxynucleotidyl transferase-mediated nick end labeling, and CD31. Tumor-secreted insulin-like growth factor binding protein (IGFBP)-3 and vascular endothelial growth factor (VEGF) were quantified in plasma by ELISA.
RESULTS: IP6 feeding resulted in suppression of hormone-refractory human prostate tumor growth without any adverse effect on body weight gain, diet, and water consumption during entire study. At the end of study, tumor growth inhibition by 1 and 2% IP6 feeding was 47 and 66% (P = 0.049-0.012) in terms of tumor volume/mouse and 40 and 66% (P = 0.08-0.003) in terms of tumor weight/mouse, respectively. Tumor xenografts from IP6-fed mice showed significantly (P < 0.001) decreased proliferating cell nuclear antigen-positive cells but increased apoptotic cells. Tumor-secreted IGFBP-3 levels were also increased up to 1.7-fold in IP6-fed groups. Additionally, IP6 strongly decreased tumor microvessel density and inhibited tumor-secreted VEGF levels.
CONCLUSIONS: IP6 suppresses hormone-refractory PCA growth accompanied by inhibition of tumor cell proliferation and angiogenesis and increased apoptosis. IP6-caused increase in IGFBP-3 and decrease in VEGF might have a role in PCA growth control.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734476     DOI: 10.1158/1078-0432.ccr-1080-3

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

1.  Inositol hexaphosphate-induced enhancement of natural killer cell activity correlates with suppression of colon carcinogenesis in rats.

Authors:  Zheng Zhang; Yang Song; Xiu-Li Wang
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

2.  p21/Cip1 and p27/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer.

Authors:  Srirupa Roy; Mallikarjuna Gu; Kumaraguruparan Ramasamy; Rana P Singh; Chapla Agarwal; Sunitha Siriwardana; Robert A Sclafani; Rajesh Agarwal
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

3.  Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study.

Authors:  Ivan Bacić; Nikica Druzijanić; Robert Karlo; Ivan Skifić; Stjepan Jagić
Journal:  J Exp Clin Cancer Res       Date:  2010-02-12

4.  Apoptotic effect of IP(6) was not enhanced by co-treatment with myo-inositol in prostate carcinoma PC3 cells.

Authors:  Hyun-Jung Kim; Yu-Mi Jang; Harriet Kim; Young Hye Kwon
Journal:  Nutr Res Pract       Date:  2007-09-30       Impact factor: 1.926

5.  Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target.

Authors:  Mallikarjuna Gu; Srirupa Roy; Komal Raina; Chapla Agarwal; Rajesh Agarwal
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

6.  Inositol hexaphosphate inhibits tumor growth, vascularity, and metabolism in TRAMP mice: a multiparametric magnetic resonance study.

Authors:  Komal Raina; Kameswaran Ravichandran; Subapriya Rajamanickam; Kendra M Huber; Natalie J Serkova; Rajesh Agarwal
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-04

7.  Phase II study of sunitinib in men with advanced prostate cancer.

Authors:  M Dror Michaelson; M M Regan; W K Oh; D S Kaufman; K Olivier; S Z Michaelson; B Spicer; C Gurski; P W Kantoff; M R Smith
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

8.  Chemopreventive efficacy of inositol hexaphosphate against prostate tumor growth and progression in TRAMP mice.

Authors:  Komal Raina; Subapriya Rajamanickam; Rana P Singh; Rajesh Agarwal
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

9.  Role of inositol polyphosphates in programmed cell death.

Authors:  Rakhee Agarwal; Hamid Mumtaz; Nawab Ali
Journal:  Mol Cell Biochem       Date:  2009-03-26       Impact factor: 3.396

10.  Inositol hexaphosphate downregulates both constitutive and ligand-induced mitogenic and cell survival signaling, and causes caspase-mediated apoptotic death of human prostate carcinoma PC-3 cells.

Authors:  Mallikarjuna Gu; Komal Raina; Chapla Agarwal; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2010-01       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.